Research programme: ophthalmic therapeutics - Cella Therapeutics/Visus Therapeutics
Latest Information Update: 07 Sep 2021
At a glance
- Originator Cella Therapeutics
- Developer Cella Therapeutics; Visus Therapeutics
- Class Antiglaucomas; Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry macular degeneration; Glaucoma